To date, only one agent has entered the market: Hsp90α/β-selective inhibitor pimitespib (TAS-116) was approved in Japan in 2022 for the treatment of gastrointestinal stromal tumors (GIST) [20]. This evidence concerns the gene HSP90AA1 and gastrointestinal stromal tumor.